Western pharmaceutical companies are no longer seeking cheap 'me-too' assets in China. Instead, they are paying premium prices for genuinely innovative drugs, as evidenced by a 10x increase in deal size over five years and a surge in patent filings from the region.

Forbion identified an arbitrage: promising biotech assets in China whose originators lacked global development expertise. Their strategy is to create new Western companies, in-license these assets, and install an experienced team to unlock their "rest of world" value, a model proven by a billion-dollar exit.

For Korean biotechs, 'thinking globally' often starts regionally. A significant portion of their deals are with other Asian companies. This strategy allows them to combine technologies and create value, using partnerships in markets like Japan as a crucial step before approaching Western markets.

China has developed a first-rate biotech effort, enabling U.S. firms to buy or license preclinical assets more efficiently than building them domestically. This creates an arbitrage opportunity, leveraging China's R&D capabilities while relying on U.S. expertise and capital for global commercialization.

Candid's rapid acquisition by UCB for $2B showcases a profitable strategy: in-licensing promising but undervalued drug assets from China's innovation hub and quickly developing them for a Western market exit. This model leverages a significant valuation arbitrage between the two ecosystems.

Big Pharma's strategy differs by region: they are willing to acquire innovative US biotechs outright but prefer to only license assets from Chinese companies. This is because Chinese assets can be secured at significantly lower valuations without the complexities of a full M&A transaction, creating an exit dilemma for VCs in China.

Amidst growing uncertainty at the US FDA, biotech companies are using a specific de-risking strategy: conducting early-stage clinical trials in countries like South Korea and Australia. This global approach is not just about cost but a deliberate move to get fast, reliable early clinical data to offset domestic regulatory instability and gain a strategic advantage.

In a major strategic shift, large pharmaceutical companies are increasingly sourcing their M&A pipeline from China. Chinese assets now account for 30-40% of Big Pharma's early-stage acquisitions, up from single digits just a few years ago, primarily because they are significantly cheaper than US or European equivalents.

Unlike markets that can sustain 'me-too' drugs, South Korean biotechs strategically focus on high-risk areas like novel biology and diverse modalities. This high 'innovation quotient' is their necessary and deliberate path to global competitiveness, embracing target and modality risk as a core strategy.